Third IPR filed by an investment firm targeting pharma patents
An inter partes review petition has been filed by Ferrum Ferro Capital, challenging a patent owned by Allergan, in a continuation of a trend of hedge funds and financiers targeting large pharmaceutical companies through the Patent Trial & Appeal Board
Ferrum filed an IPR petition against one claim of an Allergan patent covering a treatment for glaucoma by administering timolol and brimonidine in a single composition. This patent was the subject of lengthy litigation against generic drug company Sandoz, with...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.